Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Clinical Data Deal Brings Solid SSRI Entrant Viibryd Though “Too Little Too Late” & Undifferentiated Profile Concerns
Tweet Send to a Friend
Needham & Company maintains a 'Hold' on Forest Laboratories (NYSE: FRX).
Needham analyst says, "FRX will acquire Clinical Data Inc ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "FRX will acquire Clinical Data Inc ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
